Biotechnology cancer Clinical Trials Prodrug

New Drug Combination Shows Promise in Treating Ovarian Cancer

Researchers at The University of Kansas Cancer Center have discovered a therapy combination that may be helpful in the treatment of certain types of ovarian cancer. Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. According to the American Cancer Society, about 22,240 women are diagnosed with ovarian cancer each year. In a preclinical study led by Dineo
Biotechnology cancer Cell Therapy

Repurposing Existing FDA-Approved Inhibitors May Provide New Treatment Approach for Ovarian Cancer

HDAC inhibitors are effective in treating ovarian tumors with mutations in the ARID1A gene. Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene. Study results were published online in Cell Reports. Ovarian cancer is the most lethal
Cancer Discovery

Research Test Identifies BRCA2 Gene Mutations That Lead to Breast, Ovarian Cancers

A new test developed by researchers at Mayo Clinic shows which mutations in the BRCA2 gene make women susceptible to developing breast or ovarian cancers. The research behind the test was published today in the American Journal of Human Genetics. “Certain inherited mutations in the BRCA2 gene have been linked to breast and ovarian cancer,” says Fergus Couch, Ph.D., lead author of the study. “This test offers an excellent way
cancer Cancer Discovery

Combination Strategy Could Hold Promise for Ovarian Cancer

 Johns Hopkins Kimmel Cancer Center researchers demonstrated that mice with ovarian cancer that received drugs to reactivate dormant genes along with other drugs that activate the immune system had a greater reduction of tumor burden and significantly longer survival than those that received any of the drugs alone. The study already spurred a clinical trial in ovarian cancer patients. The investigators, led by graduate student Meredith Stone, Ph.D.; postdoctoral fellow Kate
Cancer Discovery

Risk-reducing mastectomy questioned for BRCA mutation carriers with prior ovarian cancer

Mutations in the BRCA gene correspond to a higher lifetime risk of developing breast and ovarian cancers, and many women who carry these mutations consider undergoing mastectomy or removal of the ovaries and fallopian tubes as preventive measures. But for the subset of women with BRCA mutations who have already had ovarian cancer, risk-reducing mastectomy might not be worth the price tag. New research from the Duke Cancer Institute finds
Biotechnology cancer

New Clinical Trial Combines Two Methods to Defeat Ovarian Cancer

New clinical trial offers combination therapy to directly kill cancer cells and teach the immune system to keep them from coming back. Fewer than half of women diagnosed with ovarian cancer live for five years or more. Sarah Adams, MD, hopes her new clinical trial will change this outcome. Adams recently opened a clinical trial at The University of New Mexico Comprehensive Cancer Center to test a new approach to
Biotechnology cancer Clinical Trials Immunotherapies

New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response?

Roswell Park Study with pembrolizumab in untried combination is first ovarian cancer clinical trial to incorporate gut flora analysis A new clinical study underway at Roswell Park Cancer Institute is the first to test the combination of the immunotherapy pembrolizumab with two other drugs as treatment for recurrent epithelial ovarian cancer, and is also the first ovarian cancer clinical trial to incorporate analysis of patients’ microbiomes — the bacteria present
cancer Cancer Discovery

Yale Researchers Find Genes Behind Aggressive Ovarian And Endometrial Cancers

In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments. The findings are published in the Oct. 10 online early edition of Proceedings of the National Academy of Sciences. Endometrial and ovarian cancers are the most prevalent gynecologic tumors in women, with over 76,160 newly diagnosed cases and about
cancer Cancer Discovery

Liquid Biopsies Offer Hope for Earlier Treatment, Better Tracking of Ovarian Cancer

Researchers at the Mayo Clinic Center for Individualized Medicine have found a promising new way to monitor and treat recurrence of ovarian cancer — a hard-to-detect disease that claims many lives. New research from George Vasmatzis, Ph.D., of the Department of Laboratory Medicine and Pathology at Mayo Clinic, finds liquid biopsies from blood tests and DNA sequencing can detect a return of ovarian cancer long before a tumor reappears. That
cancer Gene Therapy Genomes

Research Explains the Role of the Gene BRCA1 in DNA Repair

Scientists at the University of Birmingham are a step closer to understanding the role of the gene BRCA1. Changes in this gene are associated with a high risk of developing breast and ovarian cancer. The research, published in Nature Structural and Molecular Biology, explains how the gene encourages the attachment of the protein, ubiquitin, to other proteins and plays a vital role in DNA repair. Should the results be confirmed